Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 16, Number 2—February 2010


Tropheryma whipplei in Patients with Pneumonia

Sabri Bousbia, Laurent Papazian, Jean-Pierre Auffray, Florence Fenollar, Claude Martin, Wenjun Li, Laurent Chiche, Bernard La Scola, and Didier RaoultComments to Author 
Author affiliations: CNRS-IRD Faculté de Médecine, Marseille, France (S. Bousbia, L. Papazian, F. Fenollar, W. Li, B. La Scola, D. Raoult); Hôpitaux Sud, Marseille (L. Papazian, J.P. Auffray, L. Chiche); Hôpital Nord, Marseille (C. Martin)

Main Article

Table 2

Demographic and clinical data on 6 intensive care unit patients with pneumonia from whom bronchoalveolar lavage samples positive for Tropheryma whipplei DNA were collected, Marseille, France, February 2007–January 2008*

Specimen no. Patient age, y/sex Immunocompromised Diagnosis Type of pneumonia Duration of MV, d Duration of ICU stay, d T. whipplei genotype Outcome
5 39/M Yes (chemotherapy) Septic shock CAP 7 10 New Survived
10 46/M Yes (splenectomy) Coma Aspiration 3 5 3 Survived
82 65/M No Coma Aspiration 16 27 New Survived
86 74/M No Pulmonary embolism VAP 42 42 New Died
183 43/M No Pancreatitis VAP 14 16 New Survived
209 74/M Yes (corticosteroids) Spinal cord injury Aspiration 81 81 ND Died

*MV, mechanical ventilation; ICU, intensive care unit; CAP, community-acquired pneumonia; VAP, ventilator-associated pneumonia; ND, not determined.
†Based on 4 highly variable genomic sequences.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO